利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

33 条记录 (耗时 0.025 秒)

    Use of isolated domains of type IV collagen to modify cell and tissue interactions
    5.
    发明授权
    Use of isolated domains of type IV collagen to modify cell and tissue interactions 失效
    使用IV型胶原的孤立结构域来修饰细胞和组织相互作用

    公开(公告)号：US06384012B1

    公开(公告)日：2002-05-07

    申请号：US09183548

    申请日：1998-10-30

    申请人： Michael P. Sarras, Jr. ,  Billy G. Hudson

    发明人： Michael P. Sarras, Jr. ,  Billy G. Hudson

    IPC分类号： C12N500

    CPC分类号： C12N5/0018 ,  A61K38/39 ,  A61K2039/505 ,  C07K16/18 ,  C12N2501/998 ,  Y10S514/801

    摘要： The instant invention demonstrates that the 7S domain of type IV collagen disrupts cell aggregation and tissue development. Structural changes in mesoglea, inhibition of cell proliferation, and changes in cell differentiation patterns accompanies the blockage of cell aggregates which indicate that blockage may be due to alterations in mesoglea (extracellular matrix) structure with accompanying effects on cell behavior. Type IV collagen has a critical role in the initial formation of mesoglea and that perturbation of mesoglea formation affects cell division, cell differentiation, and morphogenesis.

    摘要翻译： 本发明证明IV型胶原的7S结构域破坏细胞聚集和组织发育。 mesoglea的结构变化，细胞增殖的抑制和细胞分化模式的变化伴随着细胞聚集体的阻断，这表明阻塞可能是由于mesoglea（细胞外基质）结构的改变以及伴随细胞行为的影响。 IV型胶原蛋白在初始形成mesoglea中具有关键作用，并且mesoglea形成的扰动影响细胞分裂，细胞分化和形态发生。

    Method for inhibiting angiogenesis and tumors with the isolated NC1 &agr;3 chain monomer of type IV collagen
    6.
    发明授权
    Method for inhibiting angiogenesis and tumors with the isolated NC1 &agr;3 chain monomer of type IV collagen 失效
    用IV型胶原分离的NC1α3链单体抑制血管生成和肿瘤的方法

    公开(公告)号：US06358735B1

    公开(公告)日：2002-03-19

    申请号：US09618519

    申请日：2000-07-18

    申请人： Billy G. Hudson ,  Michael P. Sarras, Jr.

    发明人： Billy G. Hudson ,  Michael P. Sarras, Jr.

    IPC分类号： C07K1600

    CPC分类号： A61K38/39 ,  C12N2501/998

    摘要： The instant invention provides methods and kits for inhibiting angiogenesis, tumor growth and metastasis, and endothelial cell interactions with the extracellular matrix, involving contacting the tumor or animal tissue with at least one isolated type IV collagen NC1 &agr; chain monomer. In a specific embodiment of the invention, the isolated domain of type IV collagen comprises the NC1 (&agr;1), (&agr;2), (&agr;3), or (&agr;6) chain monomer, or protein constructs having substantially the same structure as the NC1 (&agr;1), (&agr;2), (&agr;3), or (&agr;6) chain monomer.

    摘要翻译： 本发明提供了用于抑制血管生成，肿瘤生长和转移以及与细胞外基质的内皮细胞相互作用的方法和试剂盒，包括使肿瘤或动物组织与至少一种分离的IV型胶原NC1α链单体接触。 在本发明的一个具体实施方案中，IV型胶原的分离结构域包含NC1（α1），（α2），（α3）或（α6）链单体或具有与NC1基本上相同结构的蛋白质构建体 ），（α2），（α3）或（α6）链单体。

    &agr;-3 chain type IV collagen polynucleotides
    7.
    发明授权
    &agr;-3 chain type IV collagen polynucleotides 失效
    α-3链IV型胶原多核苷酸

    公开(公告)号：US06277558B1

    公开(公告)日：2001-08-21

    申请号：US09439897

    申请日：1999-11-12

    申请人： Billy G. Hudson

    发明人： Billy G. Hudson

    IPC分类号： C12Q100

    CPC分类号： C07K14/78 ,  A61K38/00

    摘要： An isolated and substantially pure polynucleotide encoding 238 amino acids of the carboxy terminal end of the triple helical domain and all 233 amino acids of the carboxy terminal noncollageneous domain of the bovine &agr;3 chain of type IV collagen. An isolated and substantially pure polynucleotide encoding 218 amino acids of the carboxy terminal noncollagenous domain of the human &agr;3 chain of type IV collagen. Such polynucleotides are useful to express large amounts of proteins in vectors and such expressed proteins are useful to detect Goodpasture antibodies in blood and to remove Goodpasture antibodies from the bloodstream of patients suffering from Goodpasture syndrome.

    摘要翻译： 分离和基本上纯的多核苷酸，其编码三螺旋结构域的羧基末端的238个氨基酸，以及IV型胶原蛋白的牛α3链的羧基末端noncollageneous结构域的所有233个氨基酸。 编码IV型胶原人α3链的羧基末端非胶原结构域的218个氨基酸的分离且基本上纯的多核苷酸。 这样的多核苷酸可用于在载体中表达大量的蛋白质，并且这种表达的蛋白质可用于检测血液中的Goodpasture抗体，并从患有Goodpasture综合征的患者的血液中除去Goodpasture抗体。

    Use of isolated domains of type IV collagen to modify cell and tissue interactions
    8.
    发明授权
    Use of isolated domains of type IV collagen to modify cell and tissue interactions 失效
    使用IV型胶原的孤立结构域来修饰细胞和组织相互作用

    公开(公告)号：US5691182A

    公开(公告)日：1997-11-25

    申请号：US497206

    申请日：1995-06-30

    申请人： Michael P. Sarras, Jr. ,  Billy G. Hudson

    发明人： Michael P. Sarras, Jr. ,  Billy G. Hudson

    IPC分类号： A61K38/39 ,  A61M5/32 ,  A61P43/00 ,  C07K16/18 ,  C12N5/00 ,  C12N5/08 ,  A61K38/00

    CPC分类号： C12N5/0018 ,  A61K38/39 ,  C07K16/18 ,  A61K2039/505 ,  C12N2501/998 ,  Y10S514/801

    摘要： The instant invention demonstrates that the 7S domain of type IV collagen disrupts cell aggregation and tissue development. Structural changes in mesoglea, inhibition of cell proliferation, and changes in cell differentiation patterns accompanies the blockage of cell aggregates which indicate that blockage may be due to alterations in mesoglea (extracellular matrix) structure with accompanying effects on cell behavior. Type IV collagen has a critical role in the initial formation of mesoglea and that perturbation of mesoglea formation affects cell division, cell differentiation, and morphogenesis.

    摘要翻译： 本发明证明IV型胶原的7S结构域破坏细胞聚集和组织发育。 mesoglea的结构变化，细胞增殖的抑制和细胞分化模式的变化伴随着细胞聚集体的阻断，这表明阻塞可能是由于mesoglea（细胞外基质）结构的改变以及伴随细胞行为的影响。 IV型胶原蛋白在初始形成mesoglea中具有关键作用，并且mesoglea形成的扰动影响细胞分裂，细胞分化和形态发生。

    Use of Pyridoxamine to Treat and/or Prevent Disease Processes
    9.
    发明申请
    Use of Pyridoxamine to Treat and/or Prevent Disease Processes 审中-公开
    使用吡哆胺胺治疗和/或预防疾病进程

    公开(公告)号：US20100240710A1

    公开(公告)日：2010-09-23

    申请号：US12775641

    申请日：2010-05-07

    申请人： Billy G. Hudson ,  Paul Voziyan ,  Alp Ikizler

    发明人： Billy G. Hudson ,  Paul Voziyan ,  Alp Ikizler

    IPC分类号： A61K31/44 ,  A61P13/12 ,  C07D211/72

    CPC分类号： A61K31/44 ,  A61K9/0019 ,  A61K9/0053 ,  A61K31/4412

    摘要： Methods for treating and/or preventing at least one symptom of a disorder associated with oxidative stress, carbonyl stress, or combinations thereof in a subject. In some embodiments, the methods include administering to the subject an effective amount of pyridoxamine, an analog or derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing. Also provided are methods for treating or preventing a nephropathy, acute renal injury, acute renal failure, or combinations thereof in a subject, and formulations adapted for intravenous administration comprising pyridoxamine, an analog or derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing.

    摘要翻译： 用于治疗和/或预防受试者中与氧化应激，羰基应激或其组合相关的病症的至少一种症状的方法。 在一些实施方案中，所述方法包括向受试者施用有效量的吡哆胺，其类似物或衍生物，或任何前述物质的药学上可接受的盐。 还提供了用于治疗或预防受试者的肾病，急性肾衰竭或其组合的方法，以及适于静脉内施用的制剂，其包含吡哆胺，其类似物或衍生物或任何药物可接受的盐 前面的。

    Crystallized structure of type IV collagen NC1 domain hexamer
    10.
    发明授权
    Crystallized structure of type IV collagen NC1 domain hexamer 失效

    公开(公告)号：US07122517B2

    公开(公告)日：2006-10-17

    申请号：US10206699

    申请日：2002-07-26

    申请人： Billy G. Hudson ,  Munirathinam Sundaramoorthy

    发明人： Billy G. Hudson ,  Munirathinam Sundaramoorthy

    IPC分类号： A61K38/00 ,  A61K38/08 ,  A61K38/10

    CPC分类号： C07K14/78 ,  C07K2299/00

    摘要： The present invention provides a crystallized NC1 domain hexamer of Type IV collagen, and methods for making the crystal, wherein the NC1 domain hexamer is crystallized such that the three dimensional structure of the crystallized NC1 domain hexamer can be determined to a resolution of at least 3 Å or better. The present invention also provides a method for designing compounds to inhibit angiogenesis, tumor growth, tumor metastasis, endothelial cell adhesion and/or proliferation, and/or basal lamina assembly, comprising analyzing the three dimensional structure of a crystallized Type IV collagen NC1 domain hexamer produced by the methods of the invention, and identifying and synthesizing compounds that target regions of the NC1 domain that have been identified by the analysis as being important for type IV collagen heterotrimer and hexamer assembly. The present invention also provides novel polypeptides designed by the rational drug design methods of the present invention, based on an analysis of the type TV collagen NC1 hexamer structure disclosed herein.